Savara Inc.

Savara Inc.

SVRA·NASDAQ

$5.32

+1.4%
HealthcareBiotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$1.09B
EPS-0.5300
P/E Ratio-10.05
Earnings Date08/06/2026

svra

Net Income

Last Annual Value

-118.84M

3-Year CAGR

-46%

5-Year CAGR

-19%

10-Year CAGR

-12%

Savara Inc.

Savara Inc. Competitors Analysis of Net Income

SVRA · NASDAQ
CompanyNet Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
SVRA logo
Savara Inc.
NASDAQ:SVRA
-118.84M
N/AN/AN/A 
-278.67M
N/AN/AN/A
-85.78M
N/AN/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
-74.41M
N/AN/AN/A
-137.95M
N/AN/AN/A
-101.59M
N/AN/AN/A
-119.95M
N/AN/AN/A
-231.96M
N/AN/AN/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
-68.99M
N/AN/AN/A
Savara Inc.

Savara Inc. Fair Value Envelope

SVRA · NASDAQ

Our analysis suggests that SVRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.3249, this represents a potential HIDDEN relative to our calculated worth for Savara Inc..

Intrinsic Value
Current Price: $5.3249